Lipid Metabolic Vulnerabilities of Multiple Myeloma
Source : https://link.springer.com/article/10.1007/s10238-023-01174-2
Multiple myeloma (MM) is the second most common hematological malignancy worldwide, characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive bone marrow microenvironment. Metabolic dysfunctions are emerging as...
Understanding the oncogenic mechanisms of lipid metabolism and targeting lipid metabolism reprogramming to identify new MM dependencies have important scientific significance.
Recent Advances in Cellular Immunotherapy for Lymphoid Malignancies
Source : https://pubmed.ncbi.nlm.nih.gov/37964655/
Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in endogenous T-cells to kill tumor cells...
Researchers review the factors associated with CAR T-cell outcomes and recent efforts to employ CAR T cells in earlier lines of therapy. They discuss the value of bispecific T-cell engagers as off-the-shelf products with improved toxicity profiles.
Adverse Event Reporting in Randomized Clinical Trials for Multiple Myelomad
Source : https://pubmed.ncbi.nlm.nih.gov/37948080/
These findings suggest that trial investigators and sponsors regularly use minimizing terms to describe toxic effects in MM trials, and use of this terminology may not reflect actual AE rates...
Trial investigators and sponsors regularly use minimizing terms to describe toxic effects in MM trials, and use of this terminology may not reflect actual AE rates in these studies.
Detection of Circulating Normal and Tumor Plasma Cells in Newly Diagnosed Patients of Multiple Myeloma and Their Associations With Clinical and Laboratory Parameters
Source : https://www.sciencedirect.com/science/article/abs/pii/S0147027223000788?via=ihub
Circulating plasma cells (CPCs) are frequently noted in variable frequencies in the entire spectrum of plasma cells neoplasms. With advent of high sen...
This study used multi-colour flow cytometry to evaluate the load of both CTPCs & CNPCs at the time of diagnosis and at six months’ time-point of therapy, and evaluated associations of both with clinical and laboratory parameters.
CAR T-Cell Therapy for Myeloma: Where Are We Now and What is Needed to Move CAR T-Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy
Source : https://www.sciencedirect.com/science/article/pii/S2666636723016445?via=ihub
Since 2021, two B-Cell Maturation Antigen (BCMA) directed chimeric antigen receptor T-cell (CAR T-cell) therapies, Idecabtagene vicleucel (ide-cel), a...
With the anticipation of the FDA possibly expanding approval of CAR T cells to earlier lines of myeloma therapy, the American Society for Transplantation and Cellular Therapy (ASTCT) convened a group of experts to provide a comprehensive review of the studies that led to approval of CAR T-cells in late line therapy of myeloma, discuss the...